Pharma's biggest companies were inactive during September's M&A market.
Just four deals were reported on by The Pharma Letter in total, a 66% reduction on the 12 of the previous month.
Perhaps the most interesting acquisition of September was Italy-based Alfasigma buying Intercept Pharmaceuticals (Nasdaq: ICPT), a US biopharma that once appeared to be in pole position to reach western markets with the first treatment for non-alcoholic steatohepatitis (NASH), but has since suffered numerous share-busting setbacks with its candidate obeticholic acid.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze